Kornimate/medical-research-clean huggingface dataset:
harnessing mobile technology to reduce mental health disorders in college populations

Conditions: Anxiety Disorders; Depressive Disorder; Eating Disorders

Summary: the prevalence of mental health problems among college populations has risen steadily in recent decades, with one third of today's students struggling with anxiety, depression, or an eating disorder (ed). yet, only 20-40% of college students with mental disorders receive treatment. inadequacies in mental health care delivery result in prolonged illness, disease progression, poorer prognosis, and greater likelihood of relapse, highlighting the need for a new approach for detecting mental health problems and engaging college students in services. the investigators have developed a transdiagnostic, low-cost mobile health targeted prevention and intervention platform that uses population-level screening for engaging college students in tailored services that address common mental health problems. this care delivery system represents an ideal model given its use of evidence-based mobile programs, a transdiagnostic approach that addresses comorbid mental health issues, and personalized screening and intervention to increase service uptake, enhance engagement, and improve outcomes. further, this service delivery model harnesses the expertise of an interdisciplinary team of behavioral scientists, college student mental health scholars, technology researchers, and health economists. this work bridges the study team's collective leadership over the past 25 years in successfully implementing a population-based screening program in more than 160 colleges and demonstrating the effectiveness of internet-based programs for targeted prevention and intervention for anxiety, depression, and eds. through this study, investigators will test the impact of this mobile mental health platform for service delivery in a large-scale trial across a diverse range of u.s. colleges. students who screen positive or at high-risk for clinical anxiety, depression, or eds (excluding anorexia nervosa, for which more intensive medical monitoring is warranted) and who are not currently engaged in mental health services will be randomly assigned to: 1) intervention via the mobile mental health platform; or 2) referral to usual care (i.e., campus health or counseling center). participants in the study will be enrolled for 2 years and asked to complete surveys at baseline, 6 weeks, 6 months, and 2 years.


Eligibility criteria:
inclusion criteria: * undergraduate students at participating colleges and universities who are 18 years old and older. * students who screen has high risk or clinical/subclinical for anxiety, depression, and, eating disorders. * students who are not currently in treatment, i.e., in the past month exclusion criteria: * students who do not own a smartphone * students who are currently engaged in mental health treatment * students with anorexia nervosa
a new micrografting technique for vitiligo

Conditions: Vitiligo

Summary: this study evaluates micrografting using a harvesting and grafting process that has been designed by momelan technologies. the overall concept is to harvest several small pieces of skin, each measuring about 1.75 mm in diameter from a normal pigmented area using a commercially available suction blister device, adhere them to a sterile elastomeric substrate and is then place it on a recipient area prepared by epidermal dermabrasion (removal of the epidermis).

participants with vitiligo patches undergo removal of the epidermis of the affected vitiligo skin with dermabrasion. several small pieces of pigmented skin (1.75mm) from the patient are taken from another area with the use of a suction blister device. the harvested pigmented skin is adhered to a sterile elastomeric substrate and placed on the previously dermabraded affected area. originally the primary outcome was percentage of change in pigmentation with uv photos at 10 weeks in sites undergoing grafts compared to control sites. however, because we were unable to take uv photos, we had to revise our primary outcome.

Eligibility criteria:
inclusion criteria: * be 18 to 80 years old * have a diagnosis of stable vitiligo as defined by vitiligo disease activity score of 0 or 1 * has 3 comparable vitiliginous areas of trunk or extremities (excluding hands) each measuring at least 3cm×3cm in size, with at least 80% of depigmentation, and anticipated equal sun exposure. * have not used any topical therapy to patches or ultraviolet light therapy for at least 2 weeks (subjects may restart phototherapy at week 10 if desired) * be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form * agree to follow and undergo all study-related procedures exclusion criteria: * female patients who are breastfeeding, pregnant, or planning to become pregnant * patients with a history of hypertrophic scaring or keloids and psoriasis * subjects on any dose of coumadin, warfarin, plavix or at least 325 mg aspirin. * concurrent use of immunosuppressive medications such as oral steroids, tacrolimus and other cytotoxic reagents within 2 weeks of grafting) * subject who received topical therapy or uv light ( phototherapy)in last 2 weeks * patients with a positive hiv status * patients withdiabetes mellitus with a hemoglobin a1c of more than 8. * subjects with dermatologic conditions that may koebnerize such as psoriasis and lichen planus. * participation in another interventional study with potential exposure to an investigational drug within past 30 days
extension study to assess batoclimab in participants with thyroid eye disease

Conditions: Thyroid Eye Disease

Summary: this is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (imvt-1401-3201 or imvt-1401-3202). the observational cohort will assess the durability of proptosis response of feeder studies off treatment. the treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.


Eligibility criteria:
inclusion criteria: for all participants: 1. have completed the week 24 visit of the feeder study. for participants assigned to the open-label treatment cohort: 1. do not require immediate surgical intervention and is not planning corrective surgery/irradiation or medical therapy for ted during the course of the study. 2. did not permanently discontinue batoclimab additional inclusion criteria are defined in the protocol. exclusion criteria: for all participants: 1. in the investigator's judgement, the benefits of entry in the study do not outweigh the risk.

Keywords: batoclimab thyroid eye disease imvt-1401 monoclonal antibody autoimmune disorders graves' ophthalmopathy graves' orbitopathy
study of zoledronic acid, pravastatin, and lonafarnib for patients with progeria

Conditions: Progeria

Summary: hutchinson-gilford progeria syndrome (progeria) is a rare autosomal disease that results in premature death at a median age of 13 years due to cardiovascular and cerebralvascular compromise. the mutation for this disease has been identified and results in a mutant form of lamin a that cannot be de-farnesylated. this study evaluates the combination of pravastain (a statin), lonafarnib (a farnesyltransferase inhibitor) and zoledronic acid (a bisphosphonate) in an open label phase ii efficacy trial in children with progeria. these agents all target farnesylation pathways at different points. patients with genetically confirmed progeria will be eligible for this protocol. treatment will be initiated for 24 months duration. clinical and biologic parameters will be examined to assess response.


Eligibility criteria:
inclusion criteria: * genetic diagnosis: all patients must have confirmatory mutational analysis showing mutation in the lamin a gene. * clinical diagnosis: patients must display clinical signs of progeria as per the clinical trial team. * travel: patients must be willing and able to come to boston for appropriate studies and examinations at initiation of study and at months 6, 12, 18 and 24 on study. * patient must have adequate organ and marrow function as defined by the following parameters: * blood: apc (anc + bands + monocytes = apc) \> 1,000/microliters, platelets \> 75,000/microliters (transfusion independent); hemoglobin \>9g/dl. * renal: creatinine less than or equal 1.5 times normal for age or gfr \> 70 ml/min/1.73m2. * hepatic: bilirubin less than or equal to 1.5 x upper limit of normal for age; sgpt (alt) \< and sgot (ast) \< 5 x normal range for age. * pt/ptt: pt/ptt \< 120% upper limit of normal or pi approval * no overt renal, hepatic, pulmonary disease or immune dysfunction. * 25-hydroxyvitamin d ≥ 20 ng/ml within 4 weeks of bisphosphonate infusion. * signed informed consent according to institutional guidelines must be obtained and patient must begin therapy within twenty eight (28) days. exclusion criteria: * other than the drugs used in this protocol, drugs targeted to treat progeria are excluded. drugs to treat symptoms of progeria are permitted. * patients must not be taking medications that significantly affect the metabolism of lonafarnib at the time they start lonafarnib * patient must have no uncontrolled infection. * subjects who have known or suspected hypersensitivity to any of the excipients included in the formulation should not be treated. * patients must not be pregnant or breast-feeding. female patients of childbearing potential must have negative serum or urine pregnancy test. male and female patients of reproductive potential must agree to use a medically accepted form of birth control while on study and up to 10 weeks after treatment. it is permissible for female patients to take oral contraceptives or other hormonal methods while receiving treatment with lonafarnib.

Keywords: progeria
a study to compare two different formulations of lasmiditan in healthy participants

Conditions: Healthy

Summary: the main purpose of this study is to compare the amount of lasmiditan that gets into the blood stream and how long it takes the body to get rid of it, when given as a oral-disintegrating (od) tablet compared to immediate-release (ir) tablet formulation. the information about any adverse effects experienced will be collected and the tolerability of lasmiditan when administered as od tablet will also be evaluated. screening is required within 28 days prior to the start of the study. for each participant, the total duration of the clinical trial will be about 5 weeks, including screening.


Eligibility criteria:
inclusion criteria: * are overtly healthy as determined by medical evaluation. * body mass index (bmi) of 19 to 35 kilograms per meter squared (kg/m²). exclusion criteria: * have known allergies to lasmiditan, related compounds, or any components of the formulation of lasmiditan, or a history of significant atopy. * have an abnormal blood pressure and/or pulse rate, as determined by the investigator. * have clinically significant abnormalities on ecg, as determined by investigator. * have a history or presence of cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study interventions; or of interfering with the interpretation of data. * have used or are intending to use over-the-counter or prescription medication, including dietary supplements, within 14 days prior to dosing and until study discharge (apart from occasional acetaminophen, hormonal contraception, or hormone-replacement therapy).
switch strategy from etravirine (etr) to doravirine (dor) in virologically-suppressed hiv-1 infected adults with etr-resistance

Conditions: HIV-1-infection

Summary: phase iv, open-label, single arm, unicenter and pilot study on virologically suppressed hiv infected adults with etr resistance, to assess the efficacy of a switch strategy from etravirine (etr) to doravirine (dor).


Eligibility criteria:
inclusion criteria: * hiv-1-infected subjects with age ≥18 years old. * desire of the patient to simplify their art-regimen. * having plasma hiv-1 rna \< 50 copies/ml during at least the previous 24 weeks. * currently receiving an etr-containing regimen (unchanged during the previous 24 weeks). * documented pooled/historical genotype or grt in pro-viral dna must show the presence of 103n and/or 181c and/or 190a and/or 100i and/or 138k/a. exclusion criteria: * documented pooled/historical genotype or grt in pro-viral dna of any dor-drm (mutations v106a, y188l, and m230l, and combinations of v106a and l234i; v106a and f227l and l234i; and v106a and 190a and f227l). * pregnant, breastfeeding women, women with a positive pregnancy test at the time of screening, sexually active fertile women wishing to conceive or unwilling to commit to contraceptive methods, for the duration of the study and until 4 weeks after the last dose of study medication. all women are considered fertile unless they have undergone a sterilizing surgery or are over the age of 50 with spontaneous amenorrhea for over 12 months prior to study entry. * active tuberculosis infection. * any clinical condition or therapy that, in the opinion of the investigator, would make the individual unsuitable for the study or unable to comply with the dosing requirements.

Keywords: hiv doravirine etravirine
clinical study on the efficacy and safety of multiple oral administrations of shr2285 tablets in patients undergoing elective total knee arthroplasty

Conditions: Prevention of Venous Thrombosis After TKA

Summary: this study is a multi-center, randomized, open-label, double-blind, positive-controlled phase ii clinical study evaluating the efficacy and safety of different doses of shr2285 tablets vs. enoxaparin for the prevention of postoperative venous thromboembolism in patients undergoing elective unilateral total knee arthroplasty.


Eligibility criteria:
inclusion criteria: 1. understand the study procedures and methods, voluntarily participate in the study, and sign the written informed consent form (icf); 2. scheduled to undergo elective unilateral total knee arthroplasty; 3. males or females aged 40-75 years. exclusion criteria: 1. weighing less than 40 kg or greater than 135 kg; 2. allergic to contrast agents rendering the patient unable to undergo venous angiography of the lower extremities; allergic to enoxaparin or any of the ingredients listed in the package insert thereof; allergic to the investigational product or any of the ingredients thereof; 3. with malignant tumors that still require medical intervention; except for radically treated non-melanoma skin cancer, basal cell carcinoma or squamous cell skin cancer, or cervical carcinoma in situ; 4. with a history of major liver disease within 1 year; 5. with myocardial infarction, transient ischemic attack, or ischemic stroke within 6 months.
capability assessment for diet and activity (cada) model for diabetes

Conditions: Diabetes

Summary: this study investigates the capabilities related to diet, physical activity, screening, and knowledge among diabetic adults with or without a history of hospital admissions in central florida. the hypothesis is that enhancing these capabilities, based on the capability approach framework, can significantly reduce hospital readmissions and improve diabetes management outcomes.

managing diabetes effectively requires a comprehensive understanding of various capabilities, including diet, physical activity, regular screening, and diabetes-related knowledge. for diabetic adults with a history of hospital admissions, these capabilities are critical in preventing readmissions and improving overall health outcomes. the objective of this study is to extend the investigation of feasible opportunities for managing diabetes by including measures of screening practices and knowledge alongside diet and physical activity. by employing the capability approach, this research aims to provide a comprehensive assessment of how these capabilities interact with individual and environmental factors to affect diabetes management. this approach will enrich existing knowledge by highlighting the interplay between diet, activity, screening, and knowledge, and how these factors collectively impact health outcomes. it will also inform targeted interventions that address both personal and environmental determinants of diabetes management, contributing to more effective public health strategies. the study uses a survey instrument to collect data from diabetic adults who have experienced hospital admissions in central florida and those who don't. the data will be analyzed using structural equation modeling (sem) to explore the relationships and potential causal pathways between the capabilities assessed (diet, activity, screening, knowledge) and health outcomes. this approach, grounded in the capability approach framework, will help identify how each capability contributes to the management of diabetes and highlight areas for targeted interventions. this study is available in english and spanish.

Eligibility criteria:
inclusion criteria: * adults over the age of 18. * persons diagnosed with diabetes * have an email account with access to a reliable internet connection or smartphone exclusion criteria: * minors , ages under 18 * adults not diagnosed with diabetes * adults who are unable to provide consent.

Keywords: diabetes hospital admission hospital
psa antibody levels in samples from patients with prostate cancer treated on protocol ecog-e9802

Conditions: Prostate Cancer

Summary: rationale: studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. purpose: this clinical trial studies prostate-specific antigen (psa) antibody levels in samples from patients treated for prostate cancer on trial ecog-e9802.

objectives: primary * to evaluate changes in prostate-specific antigen (psa) antibody levels over time among patients treated on ecog-e9802. secondary * to characterize the concordance of psa antibody assessment between the ecog immunology laboratory and the nci immunology laboratory. outline: previously tested samples are evaluated for changes in psa antibody levels over time (from baseline to follow-up at 12 and 24 weeks) at the ecog immunology laboratory and the nci immunology laboratory. results are compared between the laboratories.

Eligibility criteria:
disease characteristics: samples collected on ecog-e9802 (a phase ii study of prostvac-v (vaccinia)/tricom and prostvac-f (fowlpox/tricom with gm-csf in patients with psa progression after local therapy for prostate cancer) patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: recurrent prostate cancer stage i prostate cancer stage iia prostate cancer stage iib prostate cancer stage iii prostate cancer
serum amyloid a protein and fetuin a levels

Conditions: Periodontal Diseases

Summary: the purpose of this study was to evaluate acute phase proteins (apps) fetuin-a and serum amyloid a (saa) levels in gingival crevicular fluid (gcf) and serum samples in periodontal health and disease.

the study population consisted totally 60 subjects consulted to bulent ecevit university, faculty of dentistry, department of periodontology whose age and sex were matched. according to study design, subjects were divided into three groups based on their periodontal parameters. patients suffering from chronic periodontitis formed the group 1 (n: 20), patients with plaque induced gingivitis formed the group 2 (n:20) and periodontal healthy patients were inserted in group 3 (n:20). after gently drying the area, gcf was sampled with filter paper using the intracrevicular method (periopaper, proflow, inc., amityville, new york, usa).two milliliters (ml) of peripheral blood was collected from each individual with sterile syringe from the antecubital fossa by venipuncture, and to separate serum component sample centrifuged at 3000g for 5 min, and immediately stored at -40°c until assayed. the quantity of fetuin-a and saa protein concentration in the samples were analyzed by sandwich enzyme-linked immunosorbent assay (elisa) procedures using commercially available kits. the spearman's rank correlation test was used to detect the relationship between gcf and serum saa and fetuin-a with gi and cal. all tests were performed using statistical software (spss inc., version 22.0, chicago, il, usa). the mean ± standard deviation with mean rank values were calculated for each parameter, based on the patients as the statistical unit. p \< 0.05 was considered to be statistically significant.

Eligibility criteria:
group 1 inclusion criteria: * gi\>1, ppd≥5mm, cal≥5mm with alveolar bone loss radiographically. * systematically healthy patients group 2 inclusion criteria: * no alveolar bone and attachment loss * inflammation signs such as redness, edema and increased bop levels, * gi≥2, ppd≤3mm, cal≤3mm. * systematically healthy patients group 3 inclusion criteria: * no bone and attachment loss, * gi=0, ppd≤3mm, cal≤3mm * systematically healthy patients exclusion criteria for all groups: * aggressive periodontitis, * oral pathologies, * patients with any other systemic diseases, * pregnant women and those in the lactation period, * patients with smoking habit and taking medication * patients received periodontal therapy in last 6 months

Keywords: serum amyloid a fetuin-a gingival crevicular fluid serum periodontal diseases
effect of diet-induced weight loss on hiv-associated metabolic syndrome

Conditions: HIV (Human Immunodeficiency Virus); Metabolic Syndrome; HIV Infections

Summary: obese hiv-positive women with metabolic syndrome (hiv-ms) and obese hiv-negative women with metabolic syndrome will be studied before and after achieving moderate (6%-8%) diet-induced weight loss. the investigators hypothesize that health markers will improve in both groups but that the improvement will be blunted in the women with hiv-ms.


Eligibility criteria:
inclusion criteria: * sedentary * obese * have either dyslipidemia (hdl \ 150), waist circumference \> 88cm, and impaired glucose tolerance or homeostasis model assessment value of \> 3 * subjects with hiv-ms must have been receiving haart for \> 6 months exclusion criteria: * medication changes in the last 3 months * diabetes mellitus * medical problems that in the opinion of the principal investigator may interfere with patient safety * substance abuse

Keywords: hiv metabolic syndrome obesity treatment experienced
long-term results after endoscopic total extraperitoneal repair of recurrent inguinal hernia

Conditions: Hernia

Summary: evaluation of long-term results for chronic pain and impairment of daily activities after endoscopic total extraperitoneal repair of recurrent inguinal hernia with inguinal pain questionnaire (ipq).

evaluation of long-term results for chronic pain and impairment of daily activities after endoscopic total extraperitoneal repair of recurrent inguinal hernia with inguinal pain questionnaire (ipq). all patients, who had a endoscopic preperitoneal mesh repair of a recurrent inguinal hernia between 1995 and 2008 were prospectively recorded and will be sent the ipq via mail.

Eligibility criteria:
inclusion criteria: * patients, who had endoscopic total extraperitoneal repair of recurrent inguinal hernia at our institution between 1995 and 2008 exclusion criteria: * none

Keywords: recurrent hernia endoscopic total extraperitoneal repair inguinal pain questionnaire